

Daunorubicin

Statut de médicament essentiel

Description générale

Daunorubicin is an anthracycline antineoplastic agent that inhibits DNA and RNA synthesis. It is used in treatment protocols for acute lymphoblastic leukaemia, acute myelogenous leukaemia and acute promyelocytic leukaemia.

INN

Daunorubicin

Codes ATC

[L01DB02](#)

Type de médicament

Chemical agent

Historique des statuts LME

Ajouté pour la première fois en 1999 ([TRS 895](#)) pour [Lymphoid leukaemia, not elsewhere classified](#)

Ajouté en 1999 ([TRS 895](#)) pour [Acute myeloid leukaemia with recurrent genetic abnormalities](#)

Ajouté en 1999 ([TRS 895](#)) pour [Myeloid leukaemia](#)

Wikipédia

[Daunorubicin](#)

DrugBank

[Daunorubicin](#)

Recommandations

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

[Lymphoid leukaemia, not elsewhere classified](#) [Myeloid leukaemia](#) [Acute myeloid leukaemia with recurrent genetic abnormalities](#)